BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25693618)

  • 1. [The role of the assessment of heavy/light chain pairs of immunoglobulin in monoclonal gammopathies].
    Ščudla V; Pika T; Minařík J
    Vnitr Lek; 2015 Jan; 61(1):60-1, 63-71. PubMed ID: 25693618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
    Ščudla V; Lochman P; Pika T; Zapletalová J; Minařík J; Bačovský J
    Cas Lek Cesk; 2015; 154(6):292-302. PubMed ID: 26750626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin heavy chain/light chain pairs (HLC, Hevylite™) assays for diagnosing and monitoring monoclonal gammopathies.
    Kraj M
    Adv Clin Exp Med; 2014; 23(1):127-33. PubMed ID: 24596015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
    Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
    Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression.
    Andrade-Campos M; Murillo-Flórez I; García-Sanz R; Giraldo P
    Clin Chem Lab Med; 2017 Aug; 55(10):1598-1604. PubMed ID: 28284031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.
    Sachchithanantham S; Berlanga O; Alvi A; Mahmood SA; Lachmann HJ; Gillmore JD; Hawkins PN; Harding S; Wechalekar AD
    Br J Haematol; 2017 Nov; 179(4):575-585. PubMed ID: 28990174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
    Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of new immunoglobulin-derived biomarkers for the diagnosis and follow-up of patients with dysglobulinemia.
    Ermak N; Nguyen-Khoa T; Alyanakian MA
    Ann Biol Clin (Paris); 2016 Oct; 74(5):597-605. PubMed ID: 27707674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Assessment of Heavy/ Light Chain Pairs of Immunoglobulin (Hevylite assay) -  Benefit for Stratification of Multiple Myeloma?].
    Ščudla V; Lochaman P; Pika T; Zapletalová J; Minařík J; Bačovský J
    Klin Onkol; 2015; 28(5):359-69. PubMed ID: 26480864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease.
    Isola I; Moreno DF; Moga E; Mena MP; Tovar N; Rodríguez-Lobato LG; Oliver-Caldés A; Salgado MC; Brasó-Maristany F; Yagüe J; Cibeira MT; Prat A; Rosiñol L; Bladé J; Fernández de Larrea C
    Ann Hematol; 2021 Dec; 100(12):2997-3005. PubMed ID: 34463804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analytical validation of the Hevylite assays for M-protein quantification.
    Jacobs JFM; Haagen IA; Lodder A; van der Kroft C; de Kat Angelino CM; Croockewit S; Nieuwenhuys E; Gelderman KA
    Clin Chem Lab Med; 2018 Jun; 56(7):1169-1175. PubMed ID: 29397379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
    Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
    Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heavy/light chain assay in the monitoring of multiple myeloma.
    Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
    Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.
    Katzmann JA; Clark R; Kyle RA; Larson DR; Therneau TM; Melton LJ; Benson JT; Colby CL; Dispenzieri A; Landgren O; Kumar S; Bradwell AR; Cerhan JR; Rajkumar SV
    Leukemia; 2013 Jan; 27(1):208-12. PubMed ID: 22781594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.
    Ludwig H; Milosavljevic D; Zojer N; Faint JM; Bradwell AR; Hübl W; Harding SJ
    Leukemia; 2013 Jan; 27(1):213-9. PubMed ID: 22955329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports.
    Gagliardi A; Carbone C; Russo A; Cuccurullo R; Lucania A; Cioppa PD; Misso G; Caraglia M; Tommasino C; Mastrullo L
    Oncol Lett; 2016 Oct; 12(4):2363-2370. PubMed ID: 27698801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients.
    Harutyunyan NM; Vardanyan S; Ghermezi M; Gottlieb J; Berenson A; Andreu-Vieyra C; Berenson JR
    Br J Haematol; 2016 Jul; 174(1):81-7. PubMed ID: 27017948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio.
    Prokaeva T; Spencer B; Sun F; O'Hara RM; Seldin DC; Connors LH; Sanchorawala V
    Amyloid; 2016 Dec; 23(4):214-220. PubMed ID: 27677679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
    Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
    Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.